Sahajanand Medical Technologies' Credit Rating Upgraded by CRISIL
CRISIL has upgraded Sahajanand Medical Technologies Limited's credit rating to CRISIL A-/Stable and SMT Cardiovascular Private Limited's to CRISIL BBB+/Stable. SMTL's rated bank facilities increased to ₹300 Crore. The upgrades reflect growing operations, sustained profitability, and a healthy financial risk profile, with SMTL's revenue reaching ₹1,214 crore in FY26.
An upgrade in credit ratings by a major agency like CRISIL can significantly improve a company's borrowing costs, enhance its credibility with investors and lenders, and potentially attract new business opportunities, thus having a high impact.
The credit ratings for both Sahajanand Medical Technologies Limited and its subsidiary have been upgraded, indicating improved financial health and stability, which is a positive development for the company.
CRISIL Ratings Limited has upgraded the credit ratings for the bank loan facilities of Sahajanand Medical Technologies Limited (SMT) and its wholly owned subsidiary, SMT Cardiovascular Private Limited.
For Sahajanand Medical Technologies Limited, the long-term rating has been upgraded to CRISIL A-/Stable from CRISIL BBB+/Stable, and the short-term rating to CRISIL A2+ from CRISIL A2. The rated amount for bank loan facilities has also been enhanced to ₹300 Crore from ₹280 Crore. This upgrade reflects the strengthening of SMTL group’s business risk profile, driven by growing scale of operations and sustained profitability, with a comfortable financial risk profile and adequate liquidity. Operating revenue grew by 18% in fiscal 2026 to ₹1,214 crore from ₹1,032 crore in fiscal 2025, supported by higher sales volume and improved sales realization. The operating margin remained stable at 13.14% in fiscal 2026. The company also successfully completed its IPO in October 2026.
For SMT Cardiovascular Private Limited, the long-term rating has been upgraded to CRISIL BBB+/Stable from CRISIL BBB/Stable. The rating on a ₹50 Crore long-term loan facility has been withdrawn at the company's request. The upgrade reflects the strong business risk profile of the SMT group, driven by growing scale of operations and sustained profitability. Operating revenue for the SMT group grew by 18% to ₹1,214 crore in fiscal 2026. The company receives strong support from its parent, SMTL, and benefits from the promoters' extensive experience in the healthcare equipment industry.
The ratings for both entities are supported by the promoters' extensive experience and technical expertise, sizeable market share, robust distribution network, and healthy financial risk profile. Partially offsetting these strengths are the susceptibility to raw material prices and forex rate fluctuations, exposure to regulatory risks, and large working capital requirements.
What to do with a filing like this
Sahajanand Medical Technologies Limited filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sahajanand Medical Technologies Limited. Read the original for the full detail.